IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

This study is testing a new treatment called IDP-023, given alone or combined with other antibody drugs, for people with advanced blood cancers including multiple myeloma (a cancer of plasma cells) and non-Hodgkin's lymphoma that have not responded to prior treatments. **You may be eligible if...** - You have multiple myeloma that has relapsed or stopped responding to at least 3 prior treatment regimens - Or you have non-Hodgkin's lymphoma that has relapsed or stopped responding to at least 2 prior chemotherapy regimens - You are in good overall health (ECOG 0 or 1) with a life expectancy of more than 12 weeks **You may NOT be eligible if...** - You have significant heart disease or a history of major cardiac problems - You have HIV, active hepatitis B, or hepatitis C - You have an active COVID-19 infection - You have untreated cancer that has spread to the brain or spinal fluid Talk to your doctor to see if this trial is right for you.